Navigation Links
GWU consensus report outlines new approaches for evaluating benefits and risks of obesity drugs
Date:8/14/2012

WASHINGTON, D.C. The George Washington University School of Public Health and Health Services (GW) today released a report representing consensus findings from a cross-section of stakeholders that could help transform the process used to evaluate interventions to treat obesity, a public health crisis that now affects one in three adults. The report, "Obesity Drug Outcome Measures," results from a stakeholder dialogue group convened by GW that, over a period of nine months, explored why development and approval of obesity drugs have proven so difficult.

"At a time when so many Americans suffer with obesity and are faced with limited treatment options, there has been a rising call to review the emerging science on obesity to update the framework used when evaluating obesity drugs," said Christine Ferguson, J.D., Professor in the Department of Health Policy. "The FDA, under a reauthorized Prescription Drug User Fee Act, is likely to take a wider, more comprehensive look at how drugs developed to treat obesity affect how individuals with obesity feel and function. This report may help update the risk-benefit framework."

Participants in the stakeholder group all contributed to the consensus report findings and included consumer advocates, obesity experts, researchers and clinicians. Officials from the Centers for Disease Control and Prevention (CDC), the U.S. Food and Drug Administration (FDA) and the National Institutes of Health (NIH) participated in the dialogue process, but were not asked to endorse the final report.

The consensus report outlines a series of new approaches that should be considered by the FDA when evaluating the benefits and risks of obesity drugs including:

  • Obesity affects everyone differently. Evaluating the benefits and risks of interventions should reflect the various considerations within the different categories of obesity based on feeling, functioning and health impairments.
  • Obesity drugs may provide an additional option for helping individuals who do not respond, or inadequately respond, to other interventions.
  • Potential pharmaceutical interventions should be reviewed as obesity treatments rather than weight loss agents and should be limited to only those for whom they are medically appropriate.
  • The benefit-risk evaluation of treatment with obesity drugs should extend beyond numerical weight loss to improvement in feeling and functioning.


'/>"/>
Contact: Melissa Warren
mwarren@ccapr.com
202-609-6010
Chandler Chicco Agency
Source:Eurekalert

Related medicine news :

1. Adolescents in substance abuse programs report using others med marijuana
2. Accelerated resolution therapy significantly reduces PTSD symptoms, researchers report
3. Survival rates for premature babies in high-level NICUs are better than previously reported
4. New report describes 7 essential steps toward an AIDS-free generation
5. Cost Keeps Many Americans From Good Dental Care: Report
6. Inactivity May Kill as Many Worldwide as Smoking: Report
7. Oxford University Press acquires joint ownership of Journal of Surgical Case Reports
8. Reducing Ozone Limits Would Save Lives, Report States
9. Reporting of hospital infection rates and burden of C. difficile
10. Report focuses on sustainability of infectious disease surveillance
11. 20% of U.S. Women Uninsured in 2010, Up From 15% in 2000: Report
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2017)... ... February 27, 2017 , ... Sunshine Coast Health Centre (SCHC), ... Canada, at https://www.sunshinecoasthealthcentre.ca/ , is proud to announce the addition of a ... the Centre's commitment to innovation in drug rehab and alcohol treatment strategies beyond ...
(Date:2/27/2017)... ... February 27, 2017 , ... New Jersey ranks among ... all types and genders. And the need for advanced services is growing. , ... top-rated cancer care program, in collaboration with their non-profit partners in their fight against ...
(Date:2/26/2017)... Ireland (PRWEB) , ... February 26, 2017 , ... ... as in 2011 the lab became the world’s first to be ISO/IEC 17025:2005 ... 1 (cat allergen) analysis. , ISO/IEC 17025:2005 is the globally recognised standard that ...
(Date:2/26/2017)... ... February 26, 2017 , ... IndustryArchive.Org . is announcing ... B2B Marketing. B2B Sellers will now only pay for B.A.N.T. quality sales leads based ... of IndustryArchive.Org, said, “Given the new reality that B2B buyers are controlling the sales ...
(Date:2/26/2017)... (PRWEB) , ... February 26, 2017 , ... ... patients after receiving cognitive rehabilitation, according to a study released today at the ... that cognitive rehabilitation programs are proven to be effective in improving cognitive function ...
Breaking Medicine News(10 mins):
(Date:2/27/2017)... , February 27, 2017 A recent research ... medical marijuana market alone is expected to reach a value of ... along with 28 states have legalized marijuana for medical ... Florida , North Dakota , ... were approved to use the drug in medical applications such as ...
(Date:2/27/2017)... SEATTLE , Feb. 27, 2017  CTI BioPharma Corp. ... of Adam Craig , M.D., Ph.D., as President and ... Directors effective March 20, 2017. Dr. Craig succeeds Richard ... serve on the company,s Board of Directors.  Dr. Craig has ... development in both the US and Europe ...
(Date:2/27/2017)... 27, 2017 Period October – December 2016 ... result amounted to SEK -16.4 (-6.4) million Result after tax ... before and after dilution Cash flow from operating activities amounted ... ... (0.4) million Operating result amounted to SEK -39.5 (-29.5) million ...
Breaking Medicine Technology: